Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Torii Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4551   JP3635800000

TORII PHARMACEUTICAL CO., LTD.

(4551)
  Report
Delayed Japan Exchange  -  10:46:52 2023-02-07 pm EST
3165.00 JPY   +0.48%
01/23Torii Pharmaceutical : has entered into License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan
PU
01/20Japan Tobacco urged to sell drug unit by activist shareholder LIM
RE
2022TORII PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Torii Pharmaceutical : Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan(PDF)

09/16/2022 | 02:10am EST

FOR IMMEDIATE RELEASE

Tokyo, September 16, 2022

Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced today the positive top-line results of a Phase 3 comparative study for JTE-061, conducted in Japan, for the treatment of plaque psoriasis.

JT signed an exclusive license agreement with Dermavant Sciences GmbH (Dermavant) for the development and commercialization of tapinarof, a topical, therapeutic aryl hydrocarbon receptor agonist (JTE-061), for dermatological diseases and conditions in Japan. JT also signed an exclusive license agreement with Torii for co-development and commercialization of JTE-061 in Japan. JTE-061 is being developed for patients with atopic dermatitis and plaque psoriasis.

This study is a double blind, randomized, parallel-group comparison study to evaluate the efficacy and safety of JTE-061 cream in comparison to vehicle over 12 weeks in patients with plaque psoriasis. The top-line results show that the PGA response1 at week 12, the primary endpoint of efficacy, has achieved statistical significance in comparison to vehicle. The safety of JTE-061 cream was confirmed and there were no observed issues of tolerability for the cream.

JT and Torii will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of the study and other Phase 3 studies currently being conducted.

Separately, Phase 3 clinical studies in adult and adolescent patients with atopic dermatitis and Phase 2 clinical studies in pediatric patients (aged 2 to ≤11 years) with atopic dermatitis are ongoing and being conducted in Japan. Tapinarof cream is developed by Dermavant and was approved for the treatment of plaque psoriasis on May 23, 2022 in the U.S.

ABOUT Plaque Psoriasis

Plaque Psoriasis is a chronic, systemic, inflammatory skin disease characterized by red patches and plaques with silvery scales on the skin.

1 Proportion of subjects which achieve a Physician Global Assessment (PGA) score of 0 (Clear) or 1 (Almost clear) with a minimum of 2-grade improvement from baseline. PGA score is a tool used to measure the extent area and severity of plaque psoriasis (IGA=0: Clear, 1: Almost clear, 2: Mild, 3: Moderate, 4: Severe).

ABOUT Atopic Dermatitis

Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritation or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

###

Japan Tobacco Inc. is a leading international tobacco company selling its products in more than 130 countries and regions. With approximately 55,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.

Contact for Japan Tobacco Inc.:

Contact for Torii Pharmaceutical Co., Ltd.:

Dinesh Babu Thotakura, General Manager

Corporate Planning Department

Media and Investor Relations Division

(Public Relations)

Japan Tobacco Inc. Tokyo: +81-3-6636-2026

Torii Pharmaceutical Co., Ltd. Tokyo: +81-3-3231-6814

E-mail: jt.media.relations@jt.com

E-mail: webmaster@torii.co.jp

Disclaimer

TORII Pharmaceutical Co. Ltd. published this content on 16 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2022 06:09:01 UTC.


ę Publicnow 2022
All news about TORII PHARMACEUTICAL CO., LTD.
01/23Torii Pharmaceutical : has entered into License Agreement with Nogra Pharma Limited to Dev..
PU
01/20Japan Tobacco urged to sell drug unit by activist shareholder LIM
RE
2022TORII PHARMACEUTICAL CO., LTD. : Ex-dividend day for fina..
FA
2022Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending D..
PU
2022Torii Pharmaceutical Co., Ltd. - Positive Top-line Results of Phase 3 Clinical Study of..
AQ
2022Torii Pharmaceutical : Positive Top-line Results of Phase 3 Clinical Study (Comparative St..
PU
2022Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical..
MT
2022Torii Pharmaceutical Co., Ltd. Announces Start of Phase 3 Trial of VP-102 for the Treat..
CI
2022Torii Pharmaceutical : Financial Results for the First Six Months of Fiscal Year Ending De..
PU
2022Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. - Top-line Results of Phase 3 Cli..
AQ
More news
Financials
Sales 2022 49 400 M 376 M 376 M
Net income 2022 4 260 M 32,4 M 32,4 M
Net Debt 2022 - - -
P/E ratio 2022 20,8x
Yield 2022 1,52%
Capitalization 88 430 M 673 M 673 M
Capi. / Sales 2022 1,79x
Capi. / Sales 2023 1,75x
Nbr of Employees 560
Free-Float 42,2%
Chart TORII PHARMACEUTICAL CO., LTD.
Duration : Period :
Torii Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TORII PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 3 150,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Goichi Matsuda President & Representative Director
Yukihiro Takashima Manager-Finance & Accounting
Megumi Kajiwara Deputy Manager-Information Systems
Masao Torikai Auditor
Toshio Fukuoka Auditor
Sector and Competitors
1st jan.Capi. (M$)
TORII PHARMACEUTICAL CO., LTD.7.41%662
JOHNSON & JOHNSON-7.50%427 102
ELI LILLY AND COMPANY-7.70%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-4.75%263 757